Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer

Clare Sheridan1, Julian Downward1,2

  • 1Signal Transduction Laboratory, The Francis Crick Institute, London, United Kingdom.

Insights

KRAS mutations drive lung cancer. Genetically engineered mouse models (GEMMs) of KRAS-driven non-small cell lung cancer are crucial tools for understanding lung adenocarcinoma development and biology.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC).
  • Understanding KRAS-driven lung adenocarcinoma is critical for developing targeted therapies.

Purpose of the Study:

  • To review KRAS-driven genetically engineered mouse models (GEMMs) for non-small cell lung cancer.
  • To discuss the utility and potential of these models in advancing lung cancer research.

Main Methods:

  • Overview of existing KRAS-driven GEMMs.
  • Analysis of their application in studying lung cancer biology.

Main Results:

  • GEMMs provide valuable insights into the relationship between KRAS mutations and lung cancer development.
  • These models recapitulate key features of human lung adenocarcinomas.

Conclusions:

  • KRAS-driven GEMMs are essential for dissecting the complexities of non-small cell lung cancer.
  • Further utilization of these models holds significant promise for future lung cancer research and therapeutic strategies.